SEC Form SC 13G/A filed by NuCana plc (Amendment)
$NCNA
Biotechnology: Pharmaceutical Preparations
Health Care
Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
8/30/2024 | Outperform → Mkt Perform | William Blair | |
3/3/2022 | Outperform → Market Perform | Cowen & Co. | |
11/24/2021 | $10.00 → $9.00 | Buy | HC Wainwright & Co. |
William Blair downgraded NuCana from Outperform to Mkt Perform
Cowen & Co. downgraded NuCana from Outperform to Market Perform
HC Wainwright & Co. reiterated coverage of NuCana with a rating of Buy and set a new price target of $9.00 from $10.00 previously